Compare UBER & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UBER | AZN |
|---|---|---|
| Founded | 2009 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.0B | 285.7B |
| IPO Year | 2019 | N/A |
| Metric | UBER | AZN |
|---|---|---|
| Price | $72.95 | $192.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 34 | 1 |
| Target Price | ★ $106.30 | N/A |
| AVG Volume (30 Days) | ★ 18.1M | 1.8M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.66% |
| EPS Growth | ★ 3.73 | N/A |
| EPS | ★ 4.73 | N/A |
| Revenue | ★ $52,017,000,000.00 | N/A |
| Revenue This Year | $14.30 | $10.13 |
| Revenue Next Year | $14.36 | $6.21 |
| P/E Ratio | ★ $15.83 | $31.91 |
| Revenue Growth | ★ 18.28 | N/A |
| 52 Week Low | $60.63 | $61.24 |
| 52 Week High | $101.99 | $212.71 |
| Indicator | UBER | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 57.83 |
| Support Level | $69.02 | $89.28 |
| Resistance Level | $93.58 | $211.32 |
| Average True Range (ATR) | 2.32 | 3.15 |
| MACD | 0.26 | -5.19 |
| Stochastic Oscillator | 32.78 | 7.38 |
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 202 million users who order rides or food at least once a month.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.